ECE. V. Cheryomushkina

E. V. Cheryomushkina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


E. V. Cheryomushkina has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Asymptomatic hyperuricemia and gout: Are there any differences (data from a pilot case-control study)

    by M. S. Eliseev, E. V. Panina, O. V. Zheliabina

    Asymptomatic hyperuricemia (AH) and gout are characterized by the presence of elevated uric acid (UA) levels. It is not known whether there are differences between these conditions, beyond the acute attacks of arthritis unique to gout.The aim – to identify differences in the frequency of concomitant diseases, metabolic disorders and dietary habits in patients with gout and asymptomatic hyperuricemia.Material and methods. A single-stage observational case-control study included 202 people: 101 patients each with AH and gout, matched by age and gender. The examination included collection of anamnesis and medical documentation data on the presence of cardiovascular diseases, type 2 diabetes mellitus (T2DM), nephrolithiasis; inspection and measurement of anthropometric data. The intake of medications was recorded. A survey was conducted regarding the frequency of consumption of meat, seafood and alcohol. Blood levels of glucose, sUA, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), alkaline phosphatase (ALP), creatinine, cholesterol, C-reactive protein (CRP), and ESR according to Westergren were determined. GFR was calculated using the CKD-EPI formula. All patients underwent ultrasound examination of the knee joints to determine signs of synovitis and deposition of monosodium urate (MSU) crystals.Result. In patients with gout, arterial hypertension (86 (85.1%) vs 53 (52.4%) patients, respectively; ppp=0.02), while there were no differences in the frequency of consumption of meat and seafood. Among patients with gout, there were more participants with GFR2. In patients with gout, there was a significant direct correlation between the levels of UA and ALT, creatinine, CRP, and an inverse correlation between serum UA and GFR. Ultrasound of the knee joints showed a significantly more frequent deposition of MSU crystals (46 (45.5%) vs 17 (16.8%) patients, respectively; ppConclusions. Despite the apparent commonality of gout and AH, they have a number of differences. In gout, arterial hypertension and T2DM are more often detected. Also, in patients with gout, there is a significant direct correlation between the levels of sUA and ALT, creatinine, CRP, while GFR is inversely correlated with the level of serum sUA. Among patients with AH, such correlations were not found. Gout also predicts a statistically more frequent detection of MSU crystal deposits (45.5% vs 31.1% of patients). The intake of meat and fish products did not differ in both groups.

  • Open Access

    Efficacy and safety of long-term administration of various doses of colchicine in patients with gout

    by M. S. Eliseev, M. N. Chikina, O. V. Zhelyabina, Ya. I. Kuzmina, E. V. Panina, E. L. Nasonov

    The aim – to compare the efficacy and safety of different doses of colchicine (0.5 mg/day vs 1.0 mg/day) used for the prevention of arthritis attacks in gout patients during the initiation of urate-lowering therapy.Materials and methods. The study included 96 patients diagnosed with gout. Patients were randomized into three groups: those receiving colchicine 0.5 mg/day, colchicine 1 mg/day, and those without anti-inflammatory therapy. All participants were prescribed febuxostat 80 mg/day. The duration of the observation period was 6 months. The frequency and severity of arthritis attacks, as well as the incidence of adverse events, were compared.Results. Patients who did not receive colchicine experienced arthritis attacks more frequently compared to those receiving 0.5 mg/day (p=0.03) and 1 mg/day (p=0.007). In the groups receiving colchicine 0.5 mg/day and 1.0 mg/day, the frequency of attacks did not differ significantly (p=0.6), nor did the proportion of patients who did not experience arthritis attacks – 18 (56%) and 22 (69%), respectively (p=0.3). Among patients not taking colchicine, 9 (28%) did not develop arthritis attacks (p=0.02 compared to those taking 0.5 mg/day and p=0.001 for 1 mg/day). The administration of colchicine 1 mg/day (but not 0,5 mg/day) was associated with lower pain intensity on the visual analog scale during arthritis attacks compared to the non-therapy group (p=0.04). The frequency of adverse events was comparable across the groups.Conclusion. The use of colchicine 0.5 mg/day for the prevention of arthritis attacks in gout patients is justified due to the absence of differences in efficacy compared to the higher dose. However, prescribing colchicine 1 mg/day also demonstrates a good safety profile and may be considered for the prevention of arthritis attacks.


  • Hypovitaminosis of vitamin D in patients with gout (data from a pilot study)

    by M. S. Eliseev, O. V. Zhelyabina, Ya. I. Kuzmina, M. N. Chikina, E. V. Panina, E. P. Salyanova

    The relationship between serum levels of vitamin D and uric acid (UA) in the blood may be bidirectional, yet remains unexplored in patients with gout.   The aim of this study was to identify the association between serum levels of UA and vitamin D deficiency in patients with gout.   Materials and Methods. This single-center observational study included 79 patients with a confirmed diagnosis of gout (72 [91.1 %] men and 7 [8.9 %] women) who were not receiving urate-lowering therapy (ULT). All patients underwent evaluation of uric acid (UA), vitamin D, parathyroid hormone, C-reactive protein (СRP), creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and serum calcium levels, alongside calculating the estimated glomerular filtration rate (eGFR). The levels of vitamin D and the frequency of vitamin D deficiency were compared across groups with different levels of UA in blood (quartiles):    Results. The mean level of vitamin D was below the normal reference values, at 22 (17–27) ng/mL (Median). Among the patients, 63 (80 %) exhibited vitamin D levels indicative of deficiency (< 30 ng/mL). A moderate correlation was found between vitamin D levels and serum calcium (ρ = 0.343, p = 0.002), while weak correlations were also noted between vitamin D levels and CRP (ρ = –0.204, p = 0.071) as well as parathyroid hormone (ρ = –0.216, p = 0.056). The levels of uric acid were categorized into quartiles: < 426 µmol/L, 427 to 479 µmol/L, 480 to 540 µmol/L, and ≥ 540 µmol/L. The analysis of vitamin D levels among different quartiles of UA revealed no significant relationship (p = 0.672).   Conclusions. Vitamin D deficiency is prevalent in the majority of patients with gout (80 %); however, the severity of hyperuricemia is not associated with serum vitamin D levels. Further investigations are required to identify the causes of the high frequency of vitamin D deficiency in patients with gout.


  • Open Access

    Factors affecting the frequency of arthritis attacks in patients with gout not receiving urate-lowering therapy (results of a pilot retrospective study)

    by M. S. Eliseev, O. V. Zheliabina, E. V. Panina

    Gout manifests as acute arthritis attacks, the frequency of which varies and is unpredictable.The aim of this study was to identify factors associated with the frequency of arthritis attacks in patients with gout who have not received urate-lowering therapy (ULT).Materials and methods. A retrospective cohort study included 116 patients (6 females, 110 males) with gout, with a mean age of 50.1±12.05 years, who were not receiving ULT. The frequency of arthritis attacks in the past year and the presence of subcutaneous tophi were evaluated. Analyzed factors included alcohol consumption, smoking, body mass index (BMI), blood pressure values, comorbidities, diuretic use, and laboratory tests, including serum levels of glucose, creatinine, creatine phosphokinase (CPK), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), uric acid (UA), C-reactive protein (CRP), and estimated glomerular filtration rate (eGFR).Results. The mean disease duration was 9.2 [3.9; 15.8] years. The average number of arthritis attacks per year was 5 [2; 6], with ≥4 arthritis attacks per year observed in 40% of patients, and subcutaneous tophi present in 33.6%. A weak positive correlation was found between the frequency of exacerbations and systolic blood pressure (p<0.001), serum GGT levels (p4 attacks of arthritis was significant for: presence of heredity for gout – 1.955 (95% CI: 1.224–3.121; p<0.05); presence of tophi – 1.746 (95% CI: 1.161–2.626; p=0.007); alcohol consumption – 2.656 (95% CI: 1.766–3.994; p<0.001); in the presence of a sUA level ≥540 µmol/l – 1.586 (95% CI: 1.041–2.416; p=0.031). Diuretics users had attacks more frequently (р540 µmol/L), diuretic use, and alcohol consumption.


  • Open Access

    Mechanisms of cartilage damage in gout and hyperuricemia

    by E. V. Panina

    The prevalence of hyperuricemia (HU), which can be considered the first stage of gout formation, varies in different countries and tends to increase. Uric acid (UA), even in its dissolved form, activates damage and potentiates the death of articular cartilage cells through direct cytotoxicity and a number of other pathogenetic mechanisms. The possible association of HU and osteoarthritis may be due to a number of common pathogenetic mechanisms, but the direction of this relationship is still a debatable issue. The accumulated data suggest the need for a deeper study of the relationship between gout and HU with pathological processes leading to the development and progression of osteoarthritis and bone metabolism disorders.


  • Open Access

    Prospects for prescription of urate-lowering therapy in patients with asymptomatic hyperuricemia and gout

    by E. V. Panina, M. S. Eliseev

    Gout is a chronic disease characterized by attacks of arthritis, most often of the lower extremities, which develop under conditions of prolonged hyperuricemia caused by environmental and/or genetic factors. In the last decade, there has been an increase in the prevalence of both hyperuricemia and gout, which causes concern not only among rheumatologists, but also among doctors of related specialties. This is due to the fact that uric acid, deposited not only in joints, but also in other organs and tissues, contributes to the development of cardiovascular and metabolic diseases, as well as chronic kidney disease and osteoarthritis. It has been proven that even asymptomatic hyperuricemia, and not just hyperuricemia as a component of clinical gout, contributes to a more severe course of these comorbid pathologies. Probably, the maintenance of a chronic systemic inflammatory process, oxidative stress and the formation of endothelial dysfunction play a decisive role in the nosogenesis of polypathology. Accumulated scientific evidence suggests that achieving target levels of uric acid (less than 360 μmol/L in the case of atophus gout and less than 300 μmol/L in the case of tophi gout) leads to a reduction in the incidence of cerebral, cardiovascular, and renal events. Prescribing urate-lowering drugs to patients with hyperuricemia and at risk for type 2 diabetes mellitus and osteoarthritis also appears promising. Among the urate-lowering drugs registered in the Russian Federation, febuxostat shows the highest efficiency and safety, and also has a nephroprotective effect, which is especially important in patients with a decrease in glomerular filtration rate.The article examines in detail the effect of febuxostat on various organs and systems in patients with gout and asymptomatic hyperuricemia.


  • Open Access

    Comparison of colorimetric and electrochemical (Easy Touch GCU Meter) methods for determination of blood uric acid in clinical practice in patients with gout and hyperuricemia (data from a pilot study)

    by M. S. Eliseev, E. V. Panina, O. V. Zheliabina

    Hyperuricemia (HU) is a condition caused by an increase in serum uric acid (UA) levels above 360 μmol/l. Often HU is asymptomatic, but under the influence of genetic and environmental factors, attacks of peripheral arthritis (gout) may occur. Remission of gout is achieved by normalization of UA serum levels, which can be determined by a colorimetric or electrochemical method, although the latter is not currently commonly used in clinical practice to control UA levels.   Objective: to compare the standard colorimetric and electrochemical methods (Easy Touch GCU Meter) for monitoring UA levels.   Material and methods. 30 gout patients were included in the study. This group included subjects with current/anamnestic asymptomatic HU andpatients with a confirmed diagnosis of gout (ACR/EULAR 2015 criteria). The examination included a general examination, history taking, and laboratory testing. The determination of UA level by the colorimetric method in venous blood serum was performed no later than 5 minutes after collection, and the determination of UA level in fresh whole capillary blood from the fingertip by the electrochemical method (Easy Touch GCU Meter) – immediately after collection.   Results and discussion. The average values of UA blood level determined by the two compared methods differed by 13.9 μmol/l (3.9 % with respect to the colorimetric method). The high value of the correlation coefficient (r = 0.86) indicates a close linear relationship between the compared results and their good agreement. The method is also applicable in patients with achieved normouricemia.   Conclusions. The method of electrochemical determination of UA level in subjects with HU and gout can be used in real clinical practice for self-monitoring.

  • Open Access

    The use of anakinra in a patient with gout and long-term follow-up of rheumatoid arthritis

    by E. V. Cheremushkina, M. S. Eliseev, A. S. Semashko, A. V. Alekseeva, A. M. Lila

    Gout is a chronic inflammatory arthropathy, caused by articular and periarticular sodium monourate (MUN) crystals deposition on the background of chronic hyperuricemia. Gout belongs to the group of autoinflammatory diseases characterized by activation of the innate immune system. In some cases, especially in women, with a long course of the disease and absence of adequate therapy, chronic arthritis is detected, which has little difference from that in rheumatoid arthritis (RA). At the same time, until recently, the combination of RA and gout was considered casuistry due to the inhibition of crystal formation by specific factors associated with RA, what is more mechanisms of inflammation development characteristic of these diseases are completely different. However, according to the latest data, the coexistence of these two diseases in one patient is possible, and the therapy of both, gout and RA (in some patients) can be successful when prescribing biological disease modifying antirheumatic drugs, in particular inhibitors of the interleukin 1 receptor (IL1r).The article presents a rare clinical case of chronic tophi gout in an elderly patient who was followed up for a long time with a diagnosis of RA, a significant improvement was achieved on therapy with the IL1r antagonist anakinra.

  • Open Access

    Sonography as method for diagnosing gout at preclinical stage (preliminary data from pilot study)

    by E. V. Cheremushkina, M. S. Eliseev, M. V. Severinova, O. V. Zhelyabina

    Gout is one of the most common rheumatic diseases, the peculiarity of which is the development in conditions of prolonged hyperuricemia (HU). The rapid increase in the incidence of gout with a slight increase in the prevalence of HU actualizes the issue of diagnosing gout at the preclinical stage.Objective. To determine the frequency of ultrasound signs of urate crystal deposition in patients with asymptomatic HU (AHU) and gout.Results. 112 patients with AHU and gout were included, the mean age in both groups was 49.7 years. Ultrasound signs of deposition of sodium monourate crystals (SMC) among patients with AHU were determined in 21.1% of the patient by ultrasound of the knee joints and 17.5% of patients by ultrasound of the feet. Patients with gout showed the same US features in 38.1% and 56.3% of cases, respectively. There is a strong correlation between the detection of SMC by ultrasound and a history of arthritis attack of the respective joints.Conclusions. The detection of SMC and concomitant HU is very common among patients with AHU, which can be considered the preclinical stage of gout.


  • Open Access

    The use of Anakinra in a patient with a combination of two autoinflammatory diseases: Familial Mediterranean fever and gout

    by M. S. Eliseev, O. V. Zheliabina, E. L. Nasonov, E. V. Cheremushkina, T. A. Korotkova, T. S. Panevin

    Along with familial Mediterranean fever (FMF), it is now considered an autoinflammatory disease and gout. The commonality of the basic mechanisms of inflammation underlying the pathogenesis of FMF and gout predetermines the possibility of using similar therapies aimed at stopping and preventing seizures (colchicine and IL-1 inhibitors). A clinical case is presented describing the presence of a combination of FMF and gout in a patient. The patient was prescribed anakinra, which proved to be effective both as a treatment for FMF and gout. The appointment of an IL-1 inhibitor fully justified expectations: already after the first injection of anakinra, the intensity of swelling and pain in the joints decreased in the patient.